Young Investigator Award (YIA)
MOASC Cary Presant Young Investigator Award
The Young Investigator Award (YIA) aims to support early-career researchers, typically those within a few years of having completed their postgraduate training, who are focused on innovative research in clinical and translational oncology. By offering support tailored to early-career researchers, YIA programs play a crucial role in fostering talent, promoting innovation, and advancing the fight against cancer through cutting-edge research. The proposed research project should be a new project intended to support clinical and translational oncology research. Projects should account for the 1-year term of the grant and the funding allocation provided, and will be assessed based on academic merit and feasibility. The final funding decision will be made by the MOASC Board of Directors.
$25,000 to accelerate clinical & translational oncology—1-year term
Program Summary
Fuel a bold new research project that advances clinical and translational oncology. Proposals must be scoped for a 1-year term and reflect the available funding. Applications will be evaluated for scientific merit and feasibility, with final funding decisions made by the MOASC Board of Directors.
Applicant Eligibility
- MD or DO with intent to practice clinical oncology
- Initiated or completed an ACGME-accredited fellowship in hematology and/or oncology
- ≤ 7 years post-fellowship completion
- Based at a Southern California institution for the full 1-year award period
Award at a Glance
- Funding: $25,000
- Number of Awards: 1
- Term: 1 year
- Focus: Clinical and translational research that advances treatment approaches for patients with cancer
Key Dates
- Submission Deadline: Friday, December 5, 2025
- Decision Date: Friday, February 6, 2026
- Presentation at MOASC Annual Meeting: Saturday, March 21, 2026
- Start of Grant Term: Wednesday, July 1, 2026
- End of Grant Term: Wednesday, June 30, 2027
How to Apply
Email the entire application as a single PDF to [email protected] by Friday, December 5, 2025.
Supported by a grant from AVEO Oncology (“AVEO”), an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer.
